CYP19A1 and Urinary incontinence: As some studies suggest severe bladder complications under prescription of tamoxifen in contrast to aromatase inhibitors [3,11], Landi et al. suppose that—as oral menopausal hormone therapy with estrogen can be associated with an increased risk for urinary incontinence—higher estrogen levels under therapy with tamoxifen compared to aromatase inhibitors can be one explanation for a higher risk for urinary incontinence [50].